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Dizocilpine (MK-801) is a non-competitive NMDA antagonist that induces schizophrenic-
like effects. It is therefore widely used in experimental models of schizophrenia including
prepulse inhibition (PPI) impairments in rodents. Nevertheless, MK-801 has never been
tested in monkeys on a PPI paradigm. In order to evaluate MK-801 effects on monkeys’
PPI, we tested eight capuchin monkeys (Sapajus spp.) using three different doses of
MK-801 (0.01; 0.02; 0.03 mg/kg). Results show PPI impairment in acute administration
of the highest dose (0.03 mg/kg). PPI impairment induced by MK-801 was reversed by
re-exposure to the PPI test throughout treatment trials, in contrast with rodent studies.
These results indicate that tolerance effect and familiarization with PPI test may reduce the
sensorimotor gating deficits induced by MK-801 in monkeys, suggesting a drug-training
interaction.
Keywords: PPI, dizocilpine (MK-801), schizophrenia, NMDA receptor, habituation
Introduction
Prepulse inhibition (PPI) impairment is characteristic of schizophrenic patients (Braff et al., 2001a;
Ludewig et al., 2003), and also usually observed in rodents after MK-801 injection (Long et al.,
2006; Arai et al., 2008; Ishii et al., 2010; Gururajan et al., 2011; Gomes et al., 2014; Khella et al., 2014;
Park et al., 2014). PPI test is characterized as a slight stimulus (prepulse) presented at a specific
interval before the startling stimulus (pulse), leading to a reduction of the startle response. In this
sense, PPI allows the evaluation of sensorimotor gating mechanisms through behavioral responses
(Graham, 1975; Braff and Geyer, 1990; Geyer et al., 2001). Deficits in PPI reflect sensorimotor
gating abnormalities that are prominent in schizophrenic patients (Braff et al., 2001a,b; Mackeprang
et al., 2002; Kumari et al., 2003; Ludewig et al., 2003; Preuss et al., 2011). Since PPI test is a simple
and direct way to measure a deficit in information processing, it is largely used in animal models,
especially in rodents (e.g., Long et al., 2006; Arai et al., 2008; Ishii et al., 2010; Gururajan et al., 2011;
Gomes et al., 2014; Khella et al., 2014; Park et al., 2014).
Hypofunction of glutamatergic receptors has been regarded as one of the explanations for
the psychopathology of schizophrenia. As others NMDA antagonists—phencyclidine (PCP) and
ketamine—MK-801 is extremely common in schizophrenia model studies. This is due to the fact
that these drugs trigger schizophrenic-like effects as seen in several studies with rodents. It has
been demonstrated that MK-801 induces recognition memory impairments, hyperactivity and
hyperlocomotion (Bradford et al., 2010; Park et al., 2014; Basurto et al., 2015), learning, memory and
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spatial memory impairments (Hikichi et al., 2013; Karamihalev
et al., 2014), social recognition deficits (Yoshimi et al., 2015),
as well as impairments in cognitive set-shifting (Svoboda et al.,
2015), and prepulse inhibition disruption (PPI) in rodents (Long
et al., 2006; Arai et al., 2008; Ishii et al., 2010; Gururajan et al.,
2011; Gomes et al., 2014; Khella et al., 2014; Park et al., 2014).
Studies with non-human primates have demonstrated that
MK-801 is effective at inducing schizophrenic-like effects. Ogura
and Aigner (1993), using rhesus monkeys (Macaca mulatta)
demonstrated that MK-801 impairs visual recognition memory.
In the same way, Buffalo et al. (1994) performed an Operant
Test Battery, also in rhesus using MK-801. They showed MK-801
effectively disrupted animals accuracy in learning, motivation,
short-term memory, and color discrimination tasks. Working
memory is also impaired by acute and chronic MK-801 treatment
in rhesus (Tsukada et al., 2005). Likewise, in common marmosets
(Callithrix jacchus jacchus), MK-801 impaired acquisition of
shape discrimination and visuospatial conditional tasks using the
Wisconsin General Test Apparatus (Harder et al., 1998; Harder
and Ridley, 2000). A more recent study with rhesus monkeys
evidenced that a single administration of MK-801 at doses of 0.02
and 0.04mg/kgwas able to impair spatial workingmemory (Wang
et al., 2012).
To our knowledge, the effects of MK-801 on PPI have not
yet been investigated in primates. Since there are significant
morphological and neuropharmacological differences between
rodents and primates (e.g., Maior et al., 2011), we employed
a whole-body PPI protocol (Saletti et al., 2014) in capuchin
monkeys (Sapajus spp.) to evaluate MK-801 effects on
sensorimotor gating.
Materials and Methods
Ethics Statement
This study was approved by the Animal Ethics Committee
of the Institute of Biology, University of Brasilia (UnBDOC
no 131791/2013). Furthermore, the procedures were conducted
according to guidelines of the Brazilian Society of Animal
Experimentation and followed the Principles of Laboratory
Animal Care (NIH publication no. 85-23, revised 1996).
Experiments were performed in Primate Center at University
of Brasilia, Brazil. Animals were allocated into pairs or triads in
home cages (3  3  1.8 m) with natural substrate, rope swings
and nest boxes. In their home cages, they were given access to
food twice a day, once early in the morning and once at the end
of the day; water was offered ad libitum by automatic drinking
tap nozzle. The subjects were always under natural conditions of
lightness and temperature. No animal was submitted to any kind
of suffering. Beyond that, in order to minimize the stress of life in
captivity, environmental enrichment for the animals is provided
in the Primate Center. It is important to emphasize that no subject
has been euthanized after this study.
Subjects
Eight capuchin monkeys (Sapajus spp.) were employed in this
study, 6 females and 2 males, weighting between 2.5 and 5 kg.
Seven animals had been used in PPI test previously (Saletti et al.,
2014), and only one female was naïve. Nonetheless, no animal was
previously exposed to the experimental drugs. All experiments
were conducted between 8 and 12 am, 5 days a week. No food or
water deprivation has been enforced, except during trials.
Startle Measurement
Prepulse inhibition tests were performed inside a primate
chamber (60  30  30 cm), built in transparent acrylic material
of 15 mm thick, placed above a wooden box (45  40  40 cm).
Animals were placed inside the chamber with its head out through
an adjustable neck hole. Two speakers (Foster Model FT96H
Frequency band; 4 KHz30 KHz) were attached to a head box
(30  30  25 cm) on the top of the chamber. The speakers
were kept each at a distance of 10 cm of the monkey’s head and
were connected to a sound generator (O’Hara & Co., Ltd., Tokyo).
On the bottom of the chamber, an accelerometer was (Inntechno
Japan Co.ltd., Model: BDK3) connected to an amplifier (O’Hara
& Co., Ltd.) which captured animal’s whole-body movement. The
whole system was connected to a recording software (Animal
Startle—PCI 6024E, developed by O’Hara & Co., Ltd.), interfaced
withWindows XP operational system (for more details see, Saletti
et al., 2014).
Prepulse inhibition tests were conducted in an acoustic isolated
room next to the subjects’ home cage. Inside the test room, a
permanent white noise was generated (65 dB) and a video camera
(Model Clone #1004124) was used to monitor the animal during
tests for animals’ safety.
Drug
MK-801 (0; 0,01; 0,02; 0,03 mg/kg—Sigma-Aldrich, Brazil) was
dissolved in Tween 80 (Sigma-Aldrich, Brazil) and 0.9% saline
(1:19) administered intramuscularly (i.m.) in a volume of 1ml/kg.
All doses were based in studies with non-human primates (Buffalo
et al., 1994; Harder et al., 1998).
Procedures
Each session test consisted in 10 equal and consecutive blocks of
3 pseudorandomized stimuli each (pulse-alone, 115 dB, 40 ms
duration; prepulse-alone, 80 dB, 20 ms duration and pulse-
prepulse, 120 ms interval). Startle response was recorded as the
maximum peak amplitude over 600 ms after each presentation.
Prepulse inhibition sessions were carried out with a 2-week
interval. A week in which the subject received either vehicle
(VEH) or any dose of MK-801 was considered a test-week.
Therefore, the washout period for MK-801 was, at least 2 weeks.
Subjects were divided into two groups: G1 received vehicle (VEH)
at the first test-week and G2 received VEH at the fourth test-
week. In the remaining test-weeks (G1: second–fourth test-weeks;
G2: first–third test-weeks), they received three different doses of
MK-801 (0.01, 0.02, 0.03 mg/kg i.m.) randomly assigned once
a test-week. Each group comprised four subjects. PPI test was
performed 20 min after MK-801 administration.
Statistical Analysis
All statistic tests were conduct in IBM SPSS Statistics Version 20.
Shapiro Wilk Test was performed to verify the normality of the
data. Since the data did not show normal distribution, Friedman’s
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FIGURE 1 | MK-801 disrupted percent of PPI only in higher dose
(0.03 mg/kg) compared to VEH. Bars indicate percent of inhibition of startle
response (mean  SEM, n = 8) for each administrated dose. *Indicates
significant difference between 0.03 mg/kg and VEH (p = 0.002) in Friedman’s
test.
Test was performed to examine the effects of MK-801 on startle
amplitude and percentage of PPI.
Wilcoxon Rank Sum Test was performed to analyze
independent data of percentage of PPI in temporal effect of
MK-801, and Wilcoxon Signed Rank Test to examine dependent
data in temporal effect of the drug.
To normalize the data, we calculated the percentage of
inhibition of the startle response for each subject by the following
formula: 100  (pulse-alone   prepulse-pulse)/pulse-alone as
done in previous PPI studies (Winslow et al., 2002, 2007; Saletti
et al., 2014).
Results with p  0.05 were considered statistically significant.
All data are represented as themean of startle amplitude or percent
of PPI standard error of mean ( SEM).
Results
Figure 1 indicates the percentage of inhibition for each randomly
assigned administration (VEH and three doses of MK-801),
regardless of experimental group. Friedman’s Test indicated a
decrease in percentage of inhibition in comparisonwithVEHonly
for the higher dose ofMK-801 (0.03mg/kg; X2 = 9.800; p= 0.002;
Figure 1, n= 8).
In Figure 2, we show the mean startle response amplitude
when pulse-alone and prepulse+pulse are considered separately,
again regardless of experimental group. In pulse-alone situation,
startle response differs only from VEH at the dose of 0.03 mg/kg
(X2 = 5.000; p = 0.025, n = 8). In prepulse+pulse stimuli, no
dose was statistically different from VEH (X2 = 7.738; p = 0.052,
n= 8).
In our test procedure, we used a repeated treatment design in
which all subjects underwent the same treatments. As explained
above, we divided the animals in two groups (G1 and G2)
and compared the PPI response between these two groups at
FIGURE 2 | MK-801 decreased startle response amplitude after
administration of the higher dose (0.03 mg/kg) compared to VEH. Bars
indicate startle response amplitude (mean  SEM, n = 8) when presented
pulse-alone trials (black bars) and prepulse+pulse trials (gray bars). *Indicates
significant difference in pulse-alone trials between 0.03 mg/kg and VEH
(p = 0.025) and 0.01 mg/kg (p = 0.014) in Friedman’s test.
the first and fourth test-weeks. This procedure was conducted
in order to evaluate a possible temporal effect of MK-801
administration. Figure 3 shows the temporal effect of MK-
801 administration. A deficit in the percent of PPI can be
seen in animals that received MK-801 at the first test-week
(MK-801/G2, n = 4), regardless of the dose that each monkey
received, in comparison to animals that received VEH at the
first test-week (VEH/G1, n = 4) (Z =  3.830; p < 0.001).
Additionally, there was an increase in PPI after repeated injections
of MK-801 and repeated PPI tests (Z =  4.359; p < 0.001), as
observed in PPI of MK-801/G2 and MK-801/G1. A statistical
difference was also observed between MK-801 at first test-
week (MK-801/G2) and VEH at fourth test-week (VEH/G2)
(Z =  2.151; p = 0.032). There was no statistical difference
between either VEH administrations regarding percentage of
inhibition (Z =  0.414; p = 0.684). Also, no difference was
found between VEH at fourth test-week (VEH/G2) and MK-
801 at fourth test-week (MK-801/G1) (Z =  0.799; p = 0.429),
nor between VEH at first test-week (VEH/G1) and MK-801
at fourth test-week (MK-801/G1) (Z =  1.116; p = 0.265;
Figure 3A).
Figure 3B shows the mean startle response amplitude when
pulse-alone and prepulse+pulse are considered separately. In
pulse-alone trials, startle response of VEH at fourth test-week
(VEH/G2) was different from all other pulse-alone (vs. VEH/G1:
Z =  2.223, p = 0.026; vs. MK-801/G2: Z =  2.850, p = 0.004;
vs. MK-801/G1: Z =  2.098, p = 0.036). In prepulse+pulse
trials, MK-801 at fourth test-week was statistically different
from all others (vs. VEH/G1: Z =  2.139, p = 0.032; vs.
VEH/G2: Z =  3.662, p < 0.001; vs. MK-801/G2: Z =  2.560,
p = 0.010). Moreover, VEH at first test-week (VEH/G1) differs
from MK-801 at first test-week (MK-801/G2) (Z =  2.035,
p= 0.042).
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FIGURE 3 | Habituation effect of MK-801 over repeated PPI sessions. (A) Circles indicate percent of PPI of G1 group (n= 4), and triangles, of G2 group (n= 4).
White symbols indicate response after VEH administration and black symbols indicate response after MK-801 administration, regardless of dose (mean  SEM).
*Indicates significant difference of MK-801/G2 compared to all of other. (MK-801/G2 vs. VEH/G1, p < 0.001; MK-801/G2 vs. MK-801/G1, p < 0.001; MK-801/G2
vs. VEH/G2, p = 0.032). (B) At the first test-week, startle amplitude on pulse trials did not differ between groups, unlike on prepulse+pulse trials. Bars indicate
startle response amplitude. Black bars demonstrate startle response on pulse-alone trials, and gray bars demonstrate startle response on prepulse-pulse trials.
*Indicates significant difference on pulse-alone trials between VEH/G2 and all other (p < 0.036). +Indicates significant difference on prepulse-pulse trials between
MK-801/G1 and all other (p < 0.032). #Indicates statistical difference on prepulse+pulse trials between VEH/G1 and MK-801/G2 (p = 0.042).
Discussion
The present study shows the effects of MK-801 on capuchin’s PPI
response. Pretreatment with MK-801 has induced a decrease in
PPI, aswell as in startle amplitude at the highest dose (0.03mg/kg).
Other MK-801 studies in primates using different paradigms also
indicate that most behavioral changes are observed at the dose
of 0.03 mg/kg or higher (Ogura and Aigner, 1993; Buffalo et al.,
1994; Harder et al., 1998). It is possible that higher doses might
be more effective at disrupting PPI. Despite that, higher doses
of MK-801 also induce a strong ataxia effect and parkinsonism,
which could have disrupted subjects’ performance on PPI task
(Crossman et al., 1989; Rupniak et al., 1992). Nevertheless,
we observed, but not quantified, changes in monkey’s motor
behavior typical of ataxia especially at 0.02 and 0.03mg/kg. Motor
disturbances, as ataxia, were previously reported in these doses
in other monkey species (Boyce et al., 1991; Rupniak et al.,
1992).
Prepulse inhibition was reduced after acute MK-801
administration, in agreement with previous studies with
rodents (e.g., Feifel and Priebe, 1999; Long et al., 2006; Gururajan
et al., 2011; Khella et al., 2014). This effect, however, is not
observed after fourth test-weeks of testing, even with 2-week
test interval, and monkeys’ PPI response becomes similar to the
first trial. As seen in Figure 3B, there was no difference in startle
response between both groups in the first test-week. On the
other hand, prepulse+pulse startle responses were significantly
different between groups in the first test-week, indicating a
clear PPI disruption. Although some studies with PPI paradigm
showed that MK-801 effects on rodents could be intensified after
repeated sessions (Schulz et al., 2001; Gomes et al., 2014), our
results indicate a reversal of PPI disruption in monkeys. Similar
results were observed in rodents after successive injections of
D2-like dopamine receptor agonists, such as amphetamine,
cocaine, apomorphine, and quinpirole (Druhan et al., 1998;
Byrnes and Hammer, 2000; Feifel et al., 2002; Culm andHammer,
2004; Culm et al., 2004; Li et al., 2011), which was interpreted
as a tolerance effect to these drugs. In the same way, tolerance
was observed after repeated administration of MK-801 in rats’
motor activity (Dall’Olio et al., 1992). In addition, the repeated
treatment with MK-801 decreased D2 receptor density (Dall’Olio
et al., 1992). Since D2 agonist could lead to PPI disruption (Ralph
and Caine, 2005), MK-801 tolerance in our study might be
attributed to a decrease in D2 receptor density. However, effects
of D2 agonists on PPI are species-dependent (Ralph and Caine,
2005).
Familiarization with test environment might also prevent MK-
801-induced impairment on PPI. Several studies with learning
and memory in rodents evidenced that NMDA antagonists
lose their effects after the animal’s familiarization with the test
environment (Shapiro and O’Connor, 1992; Uekita and Okaichi,
2005; Chan and McNally, 2009). Following this trend, Ennaceur
et al. (2011) showed that MK-801 increased anxiety level in mice
and this anxiogenic effect decreased after repeated exposures
to the experimental apparatus. Other NMDA antagonists also
induce similar effects when the animal is familiarized to the
environment (Saucier et al., 1996; Roesler et al., 1998; Sanders
and Fanselow, 2003). NMDA antagonists’ block hippocampal
long-term potentiation (LTP) and this effect can be altered by
pretraining or by familiarization to the test environment due to
latent learning (Otnaess et al., 1999; Ennaceur et al., 2011). In
addition, it is known that hippocampus is a structure related to PPI
modulation (Swerdlow et al., 2001; Wolf et al., 2006; Kohl et al.,
2013).
Although PPI reflects automatic preattentive process (Graham,
1975), higher level of cognitive process might be involved in PPI
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response. There is a positive correlation between increase PPI
and superior strategy formation abilities in humans, which could
be related to a more efficient early information process (Bitsios
et al., 2006). Furthermore, several studies have demonstrated that
directing attention to the prepulse signal increases PPI (see Li
et al., 2009, for review). In our experimental design, subjects
served as their own control, which leads to repeated trials. In
this sense, familiarization with test conditions might explain
changes in the effect of MK-801. It is also possible that PPI test
familiarizationmay have increased attention to prepulse signaling,
thus enhancing PPI response.
As reported by Li et al. (2011), PPI test consists of repeated
presentations of mild stressors startle stimuli, and the constant
repetition of this test may provoke alterations of drug effects on
PPI response. Indeed, since MK-801 half-life is approximately
2 h (Hatfield et al., 1992), and our PPI sessions were always at
least 2 weeks apart, the observed PPI reversal cannot be ascribed
to the MK-801 effect alone. Therefore, the unexpected reversal
of PPI disruption observed in the present study is suggestive of
a drug-training interaction. Similar experiments with rats and
mice found instead an increased MK-801 effect over repeated
sessions (Schulz et al., 2001; Gomes et al., 2014). In that sense, our
results underscore the neuropharmacological differences between
rodents and primates (Maior et al., 2011) and the importance
of non-human primates for basic research and preclinical
testing.
Conclusion
The present study demonstrated the effectiveness of MK-801 on
PPI disruption in capuchin monkeys. In addition, our results
suggest a drug-training interaction effect on the PPI response
after repeated administration ofMK-801. The habituation process
observed in monkeys indicates that MK-801 adverse effects, such
as sensorimotor gating impairments, may be reduced by MK-801
tolerance effect and after familiarization to PPI test. Therefore,
future PPI tests with MK-801 should employ separate treatment
groups to avoid habituation effects induced by extensive repeated
sessions.
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